Total Payments
$3,940
2024 Payments
$280.29
Companies
41
Transactions
225
Medicare Patients
1,442
Medicare Billing
$171,939
Payment Breakdown by Category
Food & Beverage$3,558 (90.3%)
Education$382.11 (9.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,558 | 219 | 90.3% |
| Education | $382.11 | 6 | 9.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $504.60 | 26 | $0 (2024) |
| Genentech USA, Inc. | $372.32 | 23 | $0 (2021) |
| PFIZER INC. | $324.63 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $244.66 | 14 | $0 (2023) |
| Amgen Inc. | $216.66 | 14 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $210.61 | 9 | $0 (2021) |
| Lilly USA, LLC | $178.66 | 9 | $0 (2024) |
| Incyte Corporation | $148.16 | 9 | $0 (2024) |
| Celgene Corporation | $137.88 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $134.20 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $280.29 | 13 | Janssen Pharmaceuticals, Inc ($53.00) |
| 2023 | $534.64 | 28 | Novartis Pharmaceuticals Corporation ($83.84) |
| 2022 | $210.56 | 11 | PFIZER INC. ($43.37) |
| 2021 | $999.35 | 58 | Janssen Biotech, Inc. ($363.45) |
| 2020 | $571.07 | 36 | Janssen Biotech, Inc. ($88.22) |
| 2019 | $370.05 | 24 | Merck Sharp & Dohme Corporation ($44.68) |
| 2018 | $124.45 | 9 | Novartis Pharmaceuticals Corporation ($41.45) |
| 2017 | $849.22 | 46 | Genentech USA, Inc. ($301.97) |
All Payment Transactions
225 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $53.00 | General |
| 08/20/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.47 | General |
| Category: Hematology/Oncology | ||||||
| 08/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Monoclonal Antibody | ||||||
| 06/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Oncology | ||||||
| 03/27/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Oncology | ||||||
| 03/26/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Oncology | ||||||
| 02/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Rare Disease | ||||||
| 01/17/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: ONCOLOGY | ||||||
| 01/05/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Oncology | ||||||
| 12/28/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $17.41 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Oncology | ||||||
| 11/29/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Oncology | ||||||
| 11/22/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.15 | General |
| 11/01/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Oncology | ||||||
| 10/18/2023 | PFIZER INC. | IBRANCE (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.07 | General |
| Category: Oncology | ||||||
| 09/20/2023 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/26/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.83 | General |
| Category: Hematology | ||||||
| 07/18/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $17.88 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 200 | 425 | $113,748 | $30,752 |
| 2022 | 5 | 235 | 337 | $87,955 | $25,326 |
| 2021 | 4 | 518 | 945 | $224,127 | $64,621 |
| 2020 | 7 | 489 | 949 | $205,000 | $51,241 |
Total Patients
1,442
Total Services
2,656
Medicare Billing
$171,939
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 107 | 281 | $73,622 | $19,550 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 34 | 34 | $17,136 | $4,664 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 46 | 90 | $15,930 | $4,332 | 27.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 20 | $7,060 | $2,205 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 123 | 211 | $51,877 | $14,646 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 37 | 37 | $13,960 | $3,750 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 45 | 58 | $9,684 | $3,029 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $7,068 | $2,170 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 16 | $5,366 | $1,731 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 273 | 580 | $141,012 | $41,772 | 29.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 92 | $32,454 | $9,773 | 30.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 143 | 233 | $36,474 | $9,504 | 26.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 40 | 40 | $14,187 | $3,571 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 170 | 408 | $93,248 | $23,737 | 25.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 164 | 341 | $51,814 | $12,733 | 24.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 48 | 83 | $25,647 | $7,399 | 28.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 63 | 63 | $25,448 | $5,718 | 22.5% |
| 38221 | Bone marrow biopsy | Facility | 2020 | 16 | 16 | $5,792 | $931.47 | 16.1% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Facility | 2020 | 17 | 17 | $2,652 | $660.94 | 24.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 11 | 21 | $399.00 | $61.74 | 15.5% |
About Dr. Michael Steinberg, MD
Dr. Michael Steinberg, MD is a Specialist healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1902801566.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Steinberg, MD has received a total of $3,940 in payments from pharmaceutical and medical device companies, with $280.29 received in 2024. These payments were reported across 225 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($3,558).
As a Medicare-enrolled provider, Steinberg has provided services to 1,442 Medicare beneficiaries, totaling 2,656 services with total Medicare billing of $171,939. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Rochester, NY
- Active Since 06/20/2005
- Last Updated 09/08/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1902801566
Products in Payments
- IMBRUVICA (Drug) $290.86
- Imbruvica (Drug) $178.68
- ERLEADA (Drug) $162.31
- JAKAFI (Drug) $132.16
- CYRAMZA (Drug) $130.27
- XTANDI (Drug) $124.50
- KEYTRUDA (Biological) $111.79
- ZEJULA (Drug) $105.47
- Avastin (Biological) $92.18
- JEVTANA (Drug) $89.79
- DARZALEX (Biological) $83.36
- VENCLEXTA (Biological) $78.44
- KISQALI (Drug) $70.59
- IBRANCE (Drug) $70.48
- PROMACTA (Drug) $62.87
- TECENTRIQ (Biological) $62.15
- Cabometyx (Drug) $58.38
- Enhertu (Drug) $58.17
- BOSULIF (Drug) $56.77
- Stivarga (Drug) $55.41
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Rochester
Dr. James Schuster, Md, MD
Specialist — Payments: $473,233
Specialist $473,233
Dr. William Omalley, M.d, M.D
Specialist — Payments: $8,843
Specialist $8,843
Dr. Maria Cordisco, M.d, M.D
Specialist — Payments: $4,012
Specialist $4,012
Dr. David Lee, M.d, M.D
Specialist — Payments: $3,712
Specialist $3,712
Dr. John Gorczyca, Md, MD
Specialist — Payments: $3,539
Specialist $3,539
Alexander Dao, M.d, M.D
Specialist — Payments: $2,246
Specialist $2,246